HCW Biologics/$HCWB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About HCW Biologics
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Ticker
$HCWB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
36
ISIN
US40423R2040
Website
HCW Biologics Metrics
BasicAdvanced
$7.5M
-
-$24.35
0.84
-
Price and volume
Market cap
$7.5M
Beta
0.84
52-week high
$17.80
52-week low
$3.55
Average daily volume
186K
Financial strength
Current ratio
0.07
Quick ratio
0.044
Long term debt to equity
-89.994
Total debt to equity
-162.808
Interest coverage (TTM)
-29.26%
Profitability
EBITDA (TTM)
-24.592
Gross margin (TTM)
23.92%
Net profit margin (TTM)
-1,712.81%
Operating margin (TTM)
-1,795.85%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-57.20%
Return on equity (TTM)
-27,725.96%
Valuation
Price to revenue (TTM)
3.035
Price to book
-0.57
Price to tangible book (TTM)
-0.57
Price to free cash flow (TTM)
-0.307
Free cash flow yield (TTM)
-325.36%
Free cash flow per share (TTM)
-1,403.91%
Growth
Revenue change (TTM)
-63.20%
Earnings per share change (TTM)
-19.40%
3-year revenue growth (CAGR)
-22.61%
3-year earnings per share growth (CAGR)
11.64%
HCW Biologics News
AllArticlesVideos
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
GlobeNewsWire·2 weeks ago
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
GlobeNewsWire·2 weeks ago
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for HCW Biologics stock?
HCW Biologics (HCWB) has a market cap of $7.5M as of July 10, 2025.
What is the P/E ratio for HCW Biologics stock?
The price to earnings (P/E) ratio for HCW Biologics (HCWB) stock is 0 as of July 10, 2025.
Does HCW Biologics stock pay dividends?
No, HCW Biologics (HCWB) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next HCW Biologics dividend payment date?
HCW Biologics (HCWB) stock does not pay dividends to its shareholders.
What is the beta indicator for HCW Biologics?
HCW Biologics (HCWB) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.